ESMO Asia 2023 | SRH-1701 for NSCLC treatment

Beung Chul Ahn, MD, National Cancer Center, Seoul, South Korea, summarizes the results of the Phase I trial (NCT05179239) assessing SHR-1701 in non-small cell lung cancer (NSCLC); the bifunctional fusion protein comprises an anti-PD-L1 antibody fused to the extracellular domain of the TGF-β receptor and is effective at blocking both respective pathways. TGF-β action has immunosuppressive functions that can contribute to cancer progression, so the focus of this study is to reshape the tumour microenvironment such that progression is not actively encouraged. SHR-1701 shows promising results and consideration for further studies as previous attempts at TGF-β inhibition have not been successful in previous trials, the challenge researchers are now presented with is the prevalence of treatment-related adverse events. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.